Divestment of the nicotine replacement therapy business outside of the US to Dr. Reddy's completed
30 September 2024: Haleon plc ("Haleon") (LSE/NYSE: HLN) today announces that it has completed the divestment of its nicotine replacement therapy ("NRT") business outside of the US.
On 26 June 2024, Haleon announced that it had entered into an agreement to sell its NRT business outside of the US to Dr. Reddy's Laboratories SA ("Dr. Reddy's"), a wholly owned subsidiary of Dr. Reddy's Laboratories Limited for total consideration of up to £500m (with additional proceeds from the transfer of inventory), which comprises an upfront payment of £458m and further deferred, performance-based consideration of up to £42m payable during 2025 and H1 2026.
Amanda Mellor
Company Secretary
Enquiries
| Investors | Media
| ||
| Sonya Ghobrial | +44 7392 784784 | Zoë Bird | +44 7736 746167 |
| Rakesh Patel | +44 7552 484646 | Gemma Thomas | +44 7985 175048 |
| Emma White | +44 7823 523562 | | |
|
Email: investor-relations@haleon.com |
Email: corporate.media@haleon.com | ||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information please visit www.haleon.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.